Hong Seok Jang
Papers
1
Total Citations
25
H-Index
1
About
Hong Seok Jang is a leading clinical researcher in radiation oncology, with a primary focus on optimizing treatment strategies for gastrointestinal and rectal cancers. His most impactful work centers on the refinement of preoperative chemoradiotherapy protocols, particularly through the phase II multi-institutional KROG 11-02 trial. This landmark study, which has garnered 25 citations, demonstrated the safety and efficacy of a two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer—a regimen that shortens treatment duration while maintaining oncologic outcomes. Jang’s contributions have helped shape modern neoadjuvant approaches, balancing tumor response with patient quality of life. His research is widely recognized for its practical implications in clinical trial design and multidisciplinary cancer care, influencing how radiation and chemotherapy are sequenced before surgery. By generating high-quality evidence through collaborative Korean Radiation Oncology Group (KROG) studies, Jang has advanced the standard of care for rectal cancer patients and provided a framework for future investigations into hypofractionated and accelerated radiotherapy schedules.
Research Focus
Key Achievements
Top Papers
- 1